Erasca, Inc. (ERAS) ROE
- 2026-06-30: ROE -79.37%.
- 2026-03-31: ROE -70.39%.
- 2025-12-31: ROE -38.30%.
- 2025-09-30: ROE -36.70%.
Complete source-backed roe history.
- Available history
- 2020-12-31 to 2026-06-30
- Data captured
Historical ROE
| Date | ROE |
|---|
| 2026-06-30 | -79.37% |
|---|
| 2026-03-31 | -70.39% |
|---|
| 2025-12-31 | -38.30% |
|---|
| 2025-09-30 | -36.70% |
|---|
| 2025-06-30 | -34.46% |
|---|
| 2025-03-31 | -39.45% |
|---|
| 2024-12-31 | -38.17% |
|---|
| 2024-09-30 | -35.36% |
|---|
| 2024-06-30 | -35.09% |
|---|
| 2024-03-31 | -43.99% |
|---|
| 2023-12-31 | -39.48% |
|---|
| 2023-09-30 | -68.03% |
|---|
| 2023-06-30 | -64.99% |
|---|
| 2023-03-31 | -61.99% |
|---|
| 2022-12-31 | -58.95% |
|---|
| 2022-09-30 | -37.78% |
|---|
| 2022-06-30 | -37.61% |
|---|
| 2022-03-31 | -33.25% |
|---|
| 2021-12-31 | -26.89% |
|---|
| 2021-09-30 | -31.93% |
|---|
| 2021-06-30 | 79.16% |
|---|
| 2021-03-31 | 74.28% |
|---|
| 2020-12-31 | 89.19% |
|---|
Annual ROE
| Date | ROE |
|---|
| 2025-12-31 | -38.30% |
|---|
| 2024-12-31 | -38.17% |
|---|
| 2023-12-31 | -39.48% |
|---|
| 2022-12-31 | -58.95% |
|---|
| 2021-12-31 | -26.89% |
|---|
| 2020-12-31 | 89.19% |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
|---|
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
|---|
| Veradermics, Inc (MANE) | United States | $4.839B | |
|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
|---|
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
|---|